Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [ ¹⁷⁷ Lu]Lu-PSMA-617 Radioligand Therapy.

ABSTRACT: Objective  [ ¹⁷⁷ Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging. Identifying high-risk patients is crucial. We evaluated pretherapeutic PSMA PET-derived parameters to predict prostate-specific antigen (PSA) response in patients undergoing [ ¹⁷⁷ Lu]Lu-PSMA-617 RLT. Materials and Methods  We conducted a retrospective analysis among 27 patients (mean age: 71.0 ± 9.5 years; range: 52-85 years) who underwent PSMA PET/computed tomography (CT) and subsequent [ ¹⁷⁷ Lu]Lu-PSMA-617 RLT between March 2019 and January 2023. After excluding patients with liver metastases, the number

SUBMITTER: Siripongsatian D 

PROVIDER: S-EPMC11419753 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature